Print

Search Results: Treatment + Endometrial Cancer (8 results)

Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors

Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers.


TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Treatment
Cancer treatment study for people with advanced solid tumors

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.


A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/245/a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer

Treatment
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.

This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.

 


Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced cancers

This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.


Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/253/testing-cancer-treatments-in-recurrent-endometrial-cancer

Treatment
Treatment study for people with endometrial cancer that has returned

This study tests the combination of two immunotherapy drugs compared to one immunotherapy drug to shrink tumors in patients with endometrial cancer that has returned after not being detected for a period of time (recurrent). The study is enrolling people with a biomarker known as dMMR.


Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)

https://www.facingourrisk.org/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum

Treatment
Advanced endometrial cancer

This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies.


Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations

https://www.facingourrisk.org/research-clinical-trials/study/168/cyh33-in-combination-with-olaparib-in-patients-with-advanced-solid-tumors-and-dna-damage-repair-mutations

Treatment
Advanced solid tumors

This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.


Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.


Additional Results on Clinicaltrials.gov Treatment + Endometrial Cancer
98 results

De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
NCT ID: NCT04386993 (https://classic.clinicaltrials.gov/show/NCT04386993)

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT ID: NCT04683653 (https://classic.clinicaltrials.gov/show/NCT04683653)

Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
NCT ID: NCT05139368 (https://classic.clinicaltrials.gov/show/NCT05139368)

Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT ID: NCT04458402 (https://classic.clinicaltrials.gov/show/NCT04458402)

Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT ID: NCT03932409 (https://classic.clinicaltrials.gov/show/NCT03932409)

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT ID: NCT05603910 (https://classic.clinicaltrials.gov/show/NCT05603910)

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
NCT ID: NCT03955978 (https://classic.clinicaltrials.gov/show/NCT03955978)

Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT ID: NCT04570553 (https://classic.clinicaltrials.gov/show/NCT04570553)

Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT ID: NCT04839614 (https://classic.clinicaltrials.gov/show/NCT04839614)

Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT ID: NCT04586959 (https://classic.clinicaltrials.gov/show/NCT04586959)

Vaginal Cuff Brachytherapy Fractionation Study
NCT ID: NCT03785288 (https://classic.clinicaltrials.gov/show/NCT03785288)

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT ID: NCT05819892 (https://classic.clinicaltrials.gov/show/NCT05819892)

Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT ID: NCT04514692 (https://classic.clinicaltrials.gov/show/NCT04514692)

The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT ID: NCT04527900 (https://classic.clinicaltrials.gov/show/NCT04527900)

A Study of Patients Receiving High-Dose Rate Brachytherapy
NCT ID: NCT00924027 (https://classic.clinicaltrials.gov/show/NCT00924027)

Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT ID: NCT04567771 (https://classic.clinicaltrials.gov/show/NCT04567771)

Pilot Window of Opportunity Trial (POET)
NCT ID: NCT06129604 (https://classic.clinicaltrials.gov/show/NCT06129604)

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT ID: NCT05990426 (https://classic.clinicaltrials.gov/show/NCT05990426)

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT ID: NCT05691010 (https://classic.clinicaltrials.gov/show/NCT05691010)

An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
NCT ID: NCT03876860 (https://classic.clinicaltrials.gov/show/NCT03876860)

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
NCT ID: NCT06046274 (https://classic.clinicaltrials.gov/show/NCT06046274)

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT ID: NCT03968406 (https://classic.clinicaltrials.gov/show/NCT03968406)

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT ID: NCT04997096 (https://classic.clinicaltrials.gov/show/NCT04997096)

Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT ID: NCT05712668 (https://classic.clinicaltrials.gov/show/NCT05712668)

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05761951 (https://classic.clinicaltrials.gov/show/NCT05761951)

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT ID: NCT05950464 (https://classic.clinicaltrials.gov/show/NCT05950464)

Genetic Testing in African Americans
NCT ID: NCT05591131 (https://classic.clinicaltrials.gov/show/NCT05591131)

Study of ART0380 in Patients With Biologically Selected Solid Tumors
NCT ID: NCT05798611 (https://classic.clinicaltrials.gov/show/NCT05798611)

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT ID: NCT05542407 (https://classic.clinicaltrials.gov/show/NCT05542407)

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT ID: NCT05646316 (https://classic.clinicaltrials.gov/show/NCT05646316)

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT ID: NCT05036681 (https://classic.clinicaltrials.gov/show/NCT05036681)

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
NCT ID: NCT06218914 (https://classic.clinicaltrials.gov/show/NCT06218914)

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
NCT ID: NCT04576104 (https://classic.clinicaltrials.gov/show/NCT04576104)

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT ID: NCT05559879 (https://classic.clinicaltrials.gov/show/NCT05559879)

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT ID: NCT05112601 (https://classic.clinicaltrials.gov/show/NCT05112601)

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer
NCT ID: NCT04585958 (https://classic.clinicaltrials.gov/show/NCT04585958)

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT ID: NCT06036836 (https://classic.clinicaltrials.gov/show/NCT06036836)

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
NCT ID: NCT05263492 (https://classic.clinicaltrials.gov/show/NCT05263492)

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT ID: NCT05691504 (https://classic.clinicaltrials.gov/show/NCT05691504)

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://classic.clinicaltrials.gov/show/NCT05269381)

Mindfulness in Endometrial and Cervical Cancer
NCT ID: NCT04512144 (https://classic.clinicaltrials.gov/show/NCT04512144)

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT ID: NCT05039801 (https://classic.clinicaltrials.gov/show/NCT05039801)

GEN1047 for Solid Tumors - First in Human (FIH) Trial
NCT ID: NCT05180474 (https://classic.clinicaltrials.gov/show/NCT05180474)

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
NCT ID: NCT03835819 (https://classic.clinicaltrials.gov/show/NCT03835819)

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT ID: NCT05554328 (https://classic.clinicaltrials.gov/show/NCT05554328)

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://classic.clinicaltrials.gov/show/NCT05489211)

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
NCT ID: NCT03526432 (https://classic.clinicaltrials.gov/show/NCT03526432)

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
NCT ID: NCT05154487 (https://classic.clinicaltrials.gov/show/NCT05154487)

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT ID: NCT05032040 (https://classic.clinicaltrials.gov/show/NCT05032040)

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://classic.clinicaltrials.gov/show/NCT04644068)

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT ID: NCT04780217 (https://classic.clinicaltrials.gov/show/NCT04780217)

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT ID: NCT04469764 (https://classic.clinicaltrials.gov/show/NCT04469764)

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://classic.clinicaltrials.gov/show/NCT05092373)

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT ID: NCT04660929 (https://classic.clinicaltrials.gov/show/NCT04660929)

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT ID: NCT05523440 (https://classic.clinicaltrials.gov/show/NCT05523440)

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT ID: NCT02628067 (https://classic.clinicaltrials.gov/show/NCT02628067)

Abemaciclib + Letrozole +/- Metformin in Recurrent or Persistent Endometrial Cancer
NCT ID: NCT03675893 (https://classic.clinicaltrials.gov/show/NCT03675893)

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT ID: NCT04851119 (https://classic.clinicaltrials.gov/show/NCT04851119)

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://classic.clinicaltrials.gov/show/NCT04704661)

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
NCT ID: NCT03008408 (https://classic.clinicaltrials.gov/show/NCT03008408)

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT ID: NCT03564340 (https://classic.clinicaltrials.gov/show/NCT03564340)

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT ID: NCT04486352 (https://classic.clinicaltrials.gov/show/NCT04486352)

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT ID: NCT05997017 (https://classic.clinicaltrials.gov/show/NCT05997017)

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://classic.clinicaltrials.gov/show/NCT05768139)

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://classic.clinicaltrials.gov/show/NCT01174121)

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT ID: NCT04080284 (https://classic.clinicaltrials.gov/show/NCT04080284)

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
NCT ID: NCT05156268 (https://classic.clinicaltrials.gov/show/NCT05156268)

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
NCT ID: NCT05705505 (https://classic.clinicaltrials.gov/show/NCT05705505)

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
NCT ID: NCT05655598 (https://classic.clinicaltrials.gov/show/NCT05655598)

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://classic.clinicaltrials.gov/show/NCT05277051)

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
NCT ID: NCT03746431 (https://classic.clinicaltrials.gov/show/NCT03746431)

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT ID: NCT02922764 (https://classic.clinicaltrials.gov/show/NCT02922764)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://classic.clinicaltrials.gov/show/NCT05564377)

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT ID: NCT04278144 (https://classic.clinicaltrials.gov/show/NCT04278144)

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT ID: NCT03682289 (https://classic.clinicaltrials.gov/show/NCT03682289)

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT ID: NCT03065062 (https://classic.clinicaltrials.gov/show/NCT03065062)

BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT ID: NCT04196257 (https://classic.clinicaltrials.gov/show/NCT04196257)

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT ID: NCT04044859 (https://classic.clinicaltrials.gov/show/NCT04044859)

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
NCT ID: NCT05572684 (https://classic.clinicaltrials.gov/show/NCT05572684)

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
NCT ID: NCT04586335 (https://classic.clinicaltrials.gov/show/NCT04586335)

A Study of DB-1303 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://classic.clinicaltrials.gov/show/NCT05150691)

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
NCT ID: NCT04104776 (https://classic.clinicaltrials.gov/show/NCT04104776)

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT ID: NCT05887492 (https://classic.clinicaltrials.gov/show/NCT05887492)

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
NCT ID: NCT04344795 (https://classic.clinicaltrials.gov/show/NCT04344795)

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT ID: NCT04925284 (https://classic.clinicaltrials.gov/show/NCT04925284)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://classic.clinicaltrials.gov/show/NCT04585750)

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://classic.clinicaltrials.gov/show/NCT02632448)

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://classic.clinicaltrials.gov/show/NCT06270706)

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT ID: NCT02611024 (https://classic.clinicaltrials.gov/show/NCT02611024)

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT ID: NCT05592626 (https://classic.clinicaltrials.gov/show/NCT05592626)

(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT ID: NCT05252416 (https://classic.clinicaltrials.gov/show/NCT05252416)

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://classic.clinicaltrials.gov/show/NCT04319757)

A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://classic.clinicaltrials.gov/show/NCT05086692)

Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT ID: NCT05500508 (https://classic.clinicaltrials.gov/show/NCT05500508)

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT ID: NCT04262466 (https://classic.clinicaltrials.gov/show/NCT04262466)

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
NCT ID: NCT04008797 (https://classic.clinicaltrials.gov/show/NCT04008797)

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT ID: NCT05548296 (https://classic.clinicaltrials.gov/show/NCT05548296)

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRĪ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://classic.clinicaltrials.gov/show/NCT04300556)


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.